Key clinical point: Addition of colchicine to standard of care (SOC) had no significant benefit in hospitalized COVID-19 patients.

Major finding: There were no significant differences between SOC alone and SOC plus colchicine groups in all-cause mortality (rate ratio [RR], 1.01; P = .77), probability of being discharged alive within 28 days (RR, 0.98; P = .44), and the risk of progressing to invasive mechanical ventilation or death (RR, 1.02; P = .47).

Study details: In the RECOVERY trial, 11,340 hospitalized COVID-19 patients were randomly assigned to receive SOC with (n=5,610) or without (n=5,730) colchicine.

Disclosures: The RECOVERY trial was funded by the UK Research and Innovation (Medical Research Council), National Institute for Health Research, and Wellcome Trust. The authors declared no competing interests.

Source: RECOVERY Collaborative Group. Lancet Respir Med. 2021 Oct 18. doi: 10.1016/ S2213-2600(21)00435-5.

Key clinical point: Addition of colchicine to standard of care (SOC) had no significant benefit in hospitalized COVID-19 patients.

Major finding: There were no significant differences between SOC alone and SOC plus colchicine groups in all-cause mortality (rate ratio [RR], 1.01; P = .77), probability of being discharged alive within 28 days (RR, 0.98; P = .44), and the risk of progressing to invasive mechanical ventilation or death (RR, 1.02; P = .47).

Study details: In the RECOVERY trial, 11,340 hospitalized COVID-19 patients were randomly assigned to receive SOC with (n=5,610) or without (n=5,730) colchicine.

Disclosures: The RECOVERY trial was funded by the UK Research and Innovation (Medical Research Council), National Institute for Health Research, and Wellcome Trust. The authors declared no competing interests.

Source: RECOVERY Collaborative Group. Lancet Respir Med. 2021 Oct 18. doi: 10.1016/ S2213-2600(21)00435-5.

Key clinical point: Addition of colchicine to standard of care (SOC) had no significant benefit in hospitalized COVID-19 patients.

Major finding: There were no significant differences between SOC alone and SOC plus colchicine groups in all-cause mortality (rate ratio [RR], 1.01; P = .77), probability of being discharged alive within 28 days (RR, 0.98; P = .44), and the risk of progressing to invasive mechanical ventilation or death (RR, 1.02; P = .47).

Study details: In the RECOVERY trial, 11,340 hospitalized COVID-19 patients were randomly assigned to receive SOC with (n=5,610) or without (n=5,730) colchicine.

Disclosures: The RECOVERY trial was funded by the UK Research and Innovation (Medical Research Council), National Institute for Health Research, and Wellcome Trust. The authors declared no competing interests.

Source: RECOVERY Collaborative Group. Lancet Respir Med. 2021 Oct 18. doi: 10.1016/ S2213-2600(21)00435-5.

Key clinical point: In patients with nonvalvular atrial fibrillation (AF), warfarin use was linked to a lower risk of SARS-CoV-2 infection and adverse COVID-19 outcomes compared with the use of direct oral anticoagulants (DOACs).

Major finding: Warfarin vs DOAC use was associated with a lower risk for testing positive for SARS-CoV-2 (adjusted hazard ratio [aHR]; 0.73; 95% CI, 0.68-0.79), COVID-19-related hospitalization (aHR, 0.75; 95% CI, 0.68-0.83), and COVID-19-related mortality (aHR, 0.74; 95% CI, 0.66-0.83).

Study details: The details come from a population-based cohort study involving 92,339 warfarin users and 280,407 DOAC users. The OpenSAFELY platform was used for data analysis.

Disclosures: The OpenSAFELY data science platform was funded by the Wellcome Trust. OpenSAFELY work was jointly funded by UKRI, NIHR, Asthma UK-BLF, and the Longitudinal Health and Wellbeing strand of the National Core Studies programme. Principal investigator B Goldacre reported relationships with various research organizations. The co-principal investigator IJ Douglas reported ties with GSK.

Source: OpenSAFELY Collaborative et al. J Hematol Oncol. 2021 Oct 19. doi: 10.1186/s13045-021-01185-0.

Key clinical point: In patients with nonvalvular atrial fibrillation (AF), warfarin use was linked to a lower risk of SARS-CoV-2 infection and adverse COVID-19 outcomes compared with the use of direct oral anticoagulants (DOACs).

Major finding: Warfarin vs DOAC use was associated with a lower risk for testing positive for SARS-CoV-2 (adjusted hazard ratio [aHR]; 0.73; 95% CI, 0.68-0.79), COVID-19-related hospitalization (aHR, 0.75; 95% CI, 0.68-0.83), and COVID-19-related mortality (aHR, 0.74; 95% CI, 0.66-0.83).

Study details: The details come from a population-based cohort study involving 92,339 warfarin users and 280,407 DOAC users. The OpenSAFELY platform was used for data analysis.

Disclosures: The OpenSAFELY data science platform was funded by the Wellcome Trust. OpenSAFELY work was jointly funded by UKRI, NIHR, Asthma UK-BLF, and the Longitudinal Health and Wellbeing strand of the National Core Studies programme. Principal investigator B Goldacre reported relationships with various research organizations. The co-principal investigator IJ Douglas reported ties with GSK.

Source: OpenSAFELY Collaborative et al. J Hematol Oncol. 2021 Oct 19. doi: 10.1186/s13045-021-01185-0.

Key clinical point: In patients with nonvalvular atrial fibrillation (AF), warfarin use was linked to a lower risk of SARS-CoV-2 infection and adverse COVID-19 outcomes compared with the use of direct oral anticoagulants (DOACs).

Major finding: Warfarin vs DOAC use was associated with a lower risk for testing positive for SARS-CoV-2 (adjusted hazard ratio [aHR]; 0.73; 95% CI, 0.68-0.79), COVID-19-related hospitalization (aHR, 0.75; 95% CI, 0.68-0.83), and COVID-19-related mortality (aHR, 0.74; 95% CI, 0.66-0.83).

Study details: The details come from a population-based cohort study involving 92,339 warfarin users and 280,407 DOAC users. The OpenSAFELY platform was used for data analysis.

Disclosures: The OpenSAFELY data science platform was funded by the Wellcome Trust. OpenSAFELY work was jointly funded by UKRI, NIHR, Asthma UK-BLF, and the Longitudinal Health and Wellbeing strand of the National Core Studies programme. Principal investigator B Goldacre reported relationships with various research organizations. The co-principal investigator IJ Douglas reported ties with GSK.

Source: OpenSAFELY Collaborative et al. J Hematol Oncol. 2021 Oct 19. doi: 10.1186/s13045-021-01185-0.

Key clinical point: There is an increased risk of neurological complications following COVID-19 vaccination; however, this risk is substantially higher following SARS-CoV-2 infection.

Major finding: There was an increased risk for Guillain-Barré syndrome and Bell’s palsy following vaccination with ChAdOx1nCoV-19 (incidence rate ratio [IRR], 2.90 [95% CI, 2.15-3.92] and 1.29 [95% CI, 1.08-1.56], respectively) and for hemorrhagic stroke following vaccination with BNT162b2 (IRR, 1.38; 95% CI, 1.12-1.71). The risk for all neurological complications was significantly higher within 28 days of a positive SARS-CoV-2 test, including Guillain-Barré syndrome (IRR, 5.25; 95% CI, 3.00-9.18).

Study details: The data come from an analysis of 20,417,752 individuals who received ChAdOx1nCoV-19 (AstraZeneca) COVID-19 vaccine, 12,134,782 who received BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine, and 2,005,280 who tested positive for COVID-19.

Disclosures: No specific funding information was available. A Sheikh, D Hunt, K Khunti, C Robertson, and J Hippisley-Cox reported ties with various research organizations and/or advisory groups. The remaining authors declared no conflict of interests.

Source: Patone M et al. Nat Med. 2021 Oct 25. doi: 10.1038/s41591-021-01556-7.

Key clinical point: There is an increased risk of neurological complications following COVID-19 vaccination; however, this risk is substantially higher following SARS-CoV-2 infection.

Major finding: There was an increased risk for Guillain-Barré syndrome and Bell’s palsy following vaccination with ChAdOx1nCoV-19 (incidence rate ratio [IRR], 2.90 [95% CI, 2.15-3.92] and 1.29 [95% CI, 1.08-1.56], respectively) and for hemorrhagic stroke following vaccination with BNT162b2 (IRR, 1.38; 95% CI, 1.12-1.71). The risk for all neurological complications was significantly higher within 28 days of a positive SARS-CoV-2 test, including Guillain-Barré syndrome (IRR, 5.25; 95% CI, 3.00-9.18).

Study details: The data come from an analysis of 20,417,752 individuals who received ChAdOx1nCoV-19 (AstraZeneca) COVID-19 vaccine, 12,134,782 who received BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine, and 2,005,280 who tested positive for COVID-19.

Disclosures: No specific funding information was available. A Sheikh, D Hunt, K Khunti, C Robertson, and J Hippisley-Cox reported ties with various research organizations and/or advisory groups. The remaining authors declared no conflict of interests.

Source: Patone M et al. Nat Med. 2021 Oct 25. doi: 10.1038/s41591-021-01556-7.

Key clinical point: There is an increased risk of neurological complications following COVID-19 vaccination; however, this risk is substantially higher following SARS-CoV-2 infection.

Major finding: There was an increased risk for Guillain-Barré syndrome and Bell’s palsy following vaccination with ChAdOx1nCoV-19 (incidence rate ratio [IRR], 2.90 [95% CI, 2.15-3.92] and 1.29 [95% CI, 1.08-1.56], respectively) and for hemorrhagic stroke following vaccination with BNT162b2 (IRR, 1.38; 95% CI, 1.12-1.71). The risk for all neurological complications was significantly higher within 28 days of a positive SARS-CoV-2 test, including Guillain-Barré syndrome (IRR, 5.25; 95% CI, 3.00-9.18).

Study details: The data come from an analysis of 20,417,752 individuals who received ChAdOx1nCoV-19 (AstraZeneca) COVID-19 vaccine, 12,134,782 who received BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine, and 2,005,280 who tested positive for COVID-19.

Disclosures: No specific funding information was available. A Sheikh, D Hunt, K Khunti, C Robertson, and J Hippisley-Cox reported ties with various research organizations and/or advisory groups. The remaining authors declared no conflict of interests.

Source: Patone M et al. Nat Med. 2021 Oct 25. doi: 10.1038/s41591-021-01556-7.

Key clinical point: HCC patients treated with lenvatinib showed longer progression-free survival compared to those treated with sorafenib (hazard ratio 0.40, P = 0.004).

Major finding:  In a propensity score matching analysis, progression-free survival was greater in HCC patients treated with lenvatinib compared to those treated with sorafenib (5.2 months vs 3.3 months, respectively); overall survival was similar between the (13.3 months vs 11.8 months, respectively).

Study details: The data come from a retrospective study of 210 adults with unresectable HCC who underwent lenvatinib or sorafenib treatment between January 2018 and August 2020.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Kuo Y-H et al. Front Oncol. 2021 Oct 25. doi: 10.3389/fonc.2021.737767.

Key clinical point: HCC patients treated with lenvatinib showed longer progression-free survival compared to those treated with sorafenib (hazard ratio 0.40, P = 0.004).

Major finding:  In a propensity score matching analysis, progression-free survival was greater in HCC patients treated with lenvatinib compared to those treated with sorafenib (5.2 months vs 3.3 months, respectively); overall survival was similar between the (13.3 months vs 11.8 months, respectively).

Study details: The data come from a retrospective study of 210 adults with unresectable HCC who underwent lenvatinib or sorafenib treatment between January 2018 and August 2020.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Kuo Y-H et al. Front Oncol. 2021 Oct 25. doi: 10.3389/fonc.2021.737767.

Key clinical point: HCC patients treated with lenvatinib showed longer progression-free survival compared to those treated with sorafenib (hazard ratio 0.40, P = 0.004).

Major finding:  In a propensity score matching analysis, progression-free survival was greater in HCC patients treated with lenvatinib compared to those treated with sorafenib (5.2 months vs 3.3 months, respectively); overall survival was similar between the (13.3 months vs 11.8 months, respectively).

Study details: The data come from a retrospective study of 210 adults with unresectable HCC who underwent lenvatinib or sorafenib treatment between January 2018 and August 2020.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Kuo Y-H et al. Front Oncol. 2021 Oct 25. doi: 10.3389/fonc.2021.737767.

Key clinical point: Both overall survival and progression-free survival rates were significantly higher in patients with unresectable HCC who were treated with TACE-MWA compared to those treated with TACE alone.

Major finding:  After propensity score matching, the 1-, 2-, and 3-year overall survival rates for patients treated with TACE-MWA were 93.6%, 80.5%, and 61.6%, respectively, compared to 72.4%, 48.9%, and 41.9%, respectively, in patients treated with TACE alone group, respectively.

Study details: The data come from a propensity score matching study of 91 adults with unresectable HCC who underwent transarterial chemoembolization (TACE) plus percutaneous microwave ablation (MWA) and 140 who underwent TACE alone at four medical centers.

Disclosures: The study was supported by the National Natural Science Foundation of China. The researchers had no financial conflicts to disclose.

Source: Li H-Z et al. J Hepatocell Carcinoma. 2021 Nov 1. doi: 10.2147/JHC.S338456.

Key clinical point: Both overall survival and progression-free survival rates were significantly higher in patients with unresectable HCC who were treated with TACE-MWA compared to those treated with TACE alone.

Major finding:  After propensity score matching, the 1-, 2-, and 3-year overall survival rates for patients treated with TACE-MWA were 93.6%, 80.5%, and 61.6%, respectively, compared to 72.4%, 48.9%, and 41.9%, respectively, in patients treated with TACE alone group, respectively.

Study details: The data come from a propensity score matching study of 91 adults with unresectable HCC who underwent transarterial chemoembolization (TACE) plus percutaneous microwave ablation (MWA) and 140 who underwent TACE alone at four medical centers.

Disclosures: The study was supported by the National Natural Science Foundation of China. The researchers had no financial conflicts to disclose.

Source: Li H-Z et al. J Hepatocell Carcinoma. 2021 Nov 1. doi: 10.2147/JHC.S338456.

Key clinical point: Both overall survival and progression-free survival rates were significantly higher in patients with unresectable HCC who were treated with TACE-MWA compared to those treated with TACE alone.

Major finding:  After propensity score matching, the 1-, 2-, and 3-year overall survival rates for patients treated with TACE-MWA were 93.6%, 80.5%, and 61.6%, respectively, compared to 72.4%, 48.9%, and 41.9%, respectively, in patients treated with TACE alone group, respectively.

Study details: The data come from a propensity score matching study of 91 adults with unresectable HCC who underwent transarterial chemoembolization (TACE) plus percutaneous microwave ablation (MWA) and 140 who underwent TACE alone at four medical centers.

Disclosures: The study was supported by the National Natural Science Foundation of China. The researchers had no financial conflicts to disclose.

Source: Li H-Z et al. J Hepatocell Carcinoma. 2021 Nov 1. doi: 10.2147/JHC.S338456.

Key clinical point: Hepatocellular carcinoma patients who achieved complete remission with postoperative treatment after reduction hepatectomy fared better than those who achieved remission without postoperative treatment.

Major finding:  The 5-year overall survival rate and mean survival time after reduction hepatectomy were 15.7% and 28.40 months for the entire study population. The 5-year overall survival and mean survival times were 37.5% and 56.55 months, respectively, for patients who achieved complete remission with postoperative treatment, compared to 6.3% and 14.84 months, respectively, for those who achieved complete remission without postoperative treatment (P = 0.0041).

Study details: The data come from a review of 30 adults with advanced hepatocellular carcinoma who underwent reduction hepatectomy at a single center between 2000 and 2018.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Asahi Y et al. World J Gastrointest Surg. 2021 Oct 27. doi: 10.4240/wjgs.v13.i10.1245.

Key clinical point: Hepatocellular carcinoma patients who achieved complete remission with postoperative treatment after reduction hepatectomy fared better than those who achieved remission without postoperative treatment.

Major finding:  The 5-year overall survival rate and mean survival time after reduction hepatectomy were 15.7% and 28.40 months for the entire study population. The 5-year overall survival and mean survival times were 37.5% and 56.55 months, respectively, for patients who achieved complete remission with postoperative treatment, compared to 6.3% and 14.84 months, respectively, for those who achieved complete remission without postoperative treatment (P = 0.0041).

Study details: The data come from a review of 30 adults with advanced hepatocellular carcinoma who underwent reduction hepatectomy at a single center between 2000 and 2018.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Asahi Y et al. World J Gastrointest Surg. 2021 Oct 27. doi: 10.4240/wjgs.v13.i10.1245.

Key clinical point: Hepatocellular carcinoma patients who achieved complete remission with postoperative treatment after reduction hepatectomy fared better than those who achieved remission without postoperative treatment.

Major finding:  The 5-year overall survival rate and mean survival time after reduction hepatectomy were 15.7% and 28.40 months for the entire study population. The 5-year overall survival and mean survival times were 37.5% and 56.55 months, respectively, for patients who achieved complete remission with postoperative treatment, compared to 6.3% and 14.84 months, respectively, for those who achieved complete remission without postoperative treatment (P = 0.0041).

Study details: The data come from a review of 30 adults with advanced hepatocellular carcinoma who underwent reduction hepatectomy at a single center between 2000 and 2018.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Asahi Y et al. World J Gastrointest Surg. 2021 Oct 27. doi: 10.4240/wjgs.v13.i10.1245.

Key clinical point: A combination of atezolizumab plus bevacizumab (ATZ+BV) caused less fatigue in HCC patients as a first-line therapy than when given as a later line therapy, based on the IMbrave150 criteria.

Major finding:  Treatment interruption due to fatigue was significantly higher in Child-Pugh B patients who received later treatment compared to Child-Pugh A patients who received early treatment (P = 0.030). In a multivariate analysis, neutrophil lymphocyte ratios and B-IMbrave150 criteria were independent predictors of objective response to the combination therapy (hazard ratios 4.591 and 4.108, respectively).

Study details: The data come from 94 adults with unresectable HCC treated with ATZ+BV at multiple centers. Of these, 46 Child-Pugh A patients received treatment early (B-IMbrave150-in) and 48 Child-Pugh B patients received the combination as first-line or later line therapy (B-IMbrave150-out).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Chuma M et al. Hepatol Res. 2021 Nov 10. doi: 10.1111/hepr.13732. 

Key clinical point: A combination of atezolizumab plus bevacizumab (ATZ+BV) caused less fatigue in HCC patients as a first-line therapy than when given as a later line therapy, based on the IMbrave150 criteria.

Major finding:  Treatment interruption due to fatigue was significantly higher in Child-Pugh B patients who received later treatment compared to Child-Pugh A patients who received early treatment (P = 0.030). In a multivariate analysis, neutrophil lymphocyte ratios and B-IMbrave150 criteria were independent predictors of objective response to the combination therapy (hazard ratios 4.591 and 4.108, respectively).

Study details: The data come from 94 adults with unresectable HCC treated with ATZ+BV at multiple centers. Of these, 46 Child-Pugh A patients received treatment early (B-IMbrave150-in) and 48 Child-Pugh B patients received the combination as first-line or later line therapy (B-IMbrave150-out).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Chuma M et al. Hepatol Res. 2021 Nov 10. doi: 10.1111/hepr.13732. 

Key clinical point: A combination of atezolizumab plus bevacizumab (ATZ+BV) caused less fatigue in HCC patients as a first-line therapy than when given as a later line therapy, based on the IMbrave150 criteria.

Major finding:  Treatment interruption due to fatigue was significantly higher in Child-Pugh B patients who received later treatment compared to Child-Pugh A patients who received early treatment (P = 0.030). In a multivariate analysis, neutrophil lymphocyte ratios and B-IMbrave150 criteria were independent predictors of objective response to the combination therapy (hazard ratios 4.591 and 4.108, respectively).

Study details: The data come from 94 adults with unresectable HCC treated with ATZ+BV at multiple centers. Of these, 46 Child-Pugh A patients received treatment early (B-IMbrave150-in) and 48 Child-Pugh B patients received the combination as first-line or later line therapy (B-IMbrave150-out).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Chuma M et al. Hepatol Res. 2021 Nov 10. doi: 10.1111/hepr.13732. 

Key clinical point: Complete response after initial treatment with TACE was significantly associated with improved survival in adults with newly diagnosed hepatocellular carcinoma.

Major finding:  After their first treatment with TACE, 22.3% of the patients achieved complete response, and these patients had a better overall survival rate over a median follow-up period of 26.6 months than those who did not achieve complete response (35.8 months vs 24.0 months, P < 0.001).

Study details: The data come from 699 adults with newly diagnosed hepatocellular carcinoma who were initially treated with transarterial chemoembolization (TACE) between 2010 and 2013.

Disclosures: The study was supported by the Chang Gung Medical Research Fund and the National Science Council, Taiwan. The researchers had no financial conflicts to disclose.

Source: Peng C-W et al. Am J Cancer Res. 2021 Oct 15. 11(10): 4956–4965. PMID: 34765303. PMCID: PMC8569367.

Key clinical point: Complete response after initial treatment with TACE was significantly associated with improved survival in adults with newly diagnosed hepatocellular carcinoma.

Major finding:  After their first treatment with TACE, 22.3% of the patients achieved complete response, and these patients had a better overall survival rate over a median follow-up period of 26.6 months than those who did not achieve complete response (35.8 months vs 24.0 months, P < 0.001).

Study details: The data come from 699 adults with newly diagnosed hepatocellular carcinoma who were initially treated with transarterial chemoembolization (TACE) between 2010 and 2013.

Disclosures: The study was supported by the Chang Gung Medical Research Fund and the National Science Council, Taiwan. The researchers had no financial conflicts to disclose.

Source: Peng C-W et al. Am J Cancer Res. 2021 Oct 15. 11(10): 4956–4965. PMID: 34765303. PMCID: PMC8569367.

Key clinical point: Complete response after initial treatment with TACE was significantly associated with improved survival in adults with newly diagnosed hepatocellular carcinoma.

Major finding:  After their first treatment with TACE, 22.3% of the patients achieved complete response, and these patients had a better overall survival rate over a median follow-up period of 26.6 months than those who did not achieve complete response (35.8 months vs 24.0 months, P < 0.001).

Study details: The data come from 699 adults with newly diagnosed hepatocellular carcinoma who were initially treated with transarterial chemoembolization (TACE) between 2010 and 2013.

Disclosures: The study was supported by the Chang Gung Medical Research Fund and the National Science Council, Taiwan. The researchers had no financial conflicts to disclose.

Source: Peng C-W et al. Am J Cancer Res. 2021 Oct 15. 11(10): 4956–4965. PMID: 34765303. PMCID: PMC8569367.

Key clinical point: Baseline neutrophil-to-lymphocyte ratio (NLR), and delta NLR were predictors of overall survival in HCC patients treated with stereotactic body radiation therapy; however, neither platelet-to-lymphocyte ratio (PLR) nor delta PLR were predictive of survival.

Major finding:  Elevations in NLR and delta-NLR (dNLR) prior to SBRT in hepatocellular carcinoma patients were significant predictors of worse overall survival (P <0.001 and P = 0.011, respectively). 

Study details: The data come from a retrospective study of 93 adult HCC patients treated with stereotactic body radiation therapy (SBRT), with a median follow-up of 10.7 months.

Disclosures: The study was supported by the Tri-Service General Hospital. The researchers had no financial conflicts to disclose.  

Source: Hsiang C-W et al. J Hepatocell Carcinoma. 2021 Oct 29. doi: 10.2147/JHC.S334933.

Key clinical point: Baseline neutrophil-to-lymphocyte ratio (NLR), and delta NLR were predictors of overall survival in HCC patients treated with stereotactic body radiation therapy; however, neither platelet-to-lymphocyte ratio (PLR) nor delta PLR were predictive of survival.

Major finding:  Elevations in NLR and delta-NLR (dNLR) prior to SBRT in hepatocellular carcinoma patients were significant predictors of worse overall survival (P <0.001 and P = 0.011, respectively). 

Study details: The data come from a retrospective study of 93 adult HCC patients treated with stereotactic body radiation therapy (SBRT), with a median follow-up of 10.7 months.

Disclosures: The study was supported by the Tri-Service General Hospital. The researchers had no financial conflicts to disclose.  

Source: Hsiang C-W et al. J Hepatocell Carcinoma. 2021 Oct 29. doi: 10.2147/JHC.S334933.

Key clinical point: Baseline neutrophil-to-lymphocyte ratio (NLR), and delta NLR were predictors of overall survival in HCC patients treated with stereotactic body radiation therapy; however, neither platelet-to-lymphocyte ratio (PLR) nor delta PLR were predictive of survival.

Major finding:  Elevations in NLR and delta-NLR (dNLR) prior to SBRT in hepatocellular carcinoma patients were significant predictors of worse overall survival (P <0.001 and P = 0.011, respectively). 

Study details: The data come from a retrospective study of 93 adult HCC patients treated with stereotactic body radiation therapy (SBRT), with a median follow-up of 10.7 months.

Disclosures: The study was supported by the Tri-Service General Hospital. The researchers had no financial conflicts to disclose.  

Source: Hsiang C-W et al. J Hepatocell Carcinoma. 2021 Oct 29. doi: 10.2147/JHC.S334933.

Key clinical point: Fever following radiofrequency ablation in hepatocellular carcinoma patients was independently associated with younger age, low serum albumin level, general anesthesia, tumor size, and tumor number.

Major finding:  The adjusted odds ratios for the independent predictors of fever in these patients were 0.96 for younger age, 0.49 for low serum albumin level, 2.06 for general anesthesia, 1.52 for tumor size, and 1.71 for tumor number. HCC patients who developed fevers after radiofrequency ablation also had significantly longer hospital stays than those without fevers (9.06 days vs 5.50 days).

Study details: The data come from a retrospective study of 272 adults with new or recurrent hepatocellular carcinoma who underwent ultrasonography-guided radiofrequency ablation (RFA) between April 2014 and February 2019.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Chen P-Y et al. Cancers (Basel). 2021 Oct 22. doi: 10.3390/cancers13215303.

Key clinical point: Fever following radiofrequency ablation in hepatocellular carcinoma patients was independently associated with younger age, low serum albumin level, general anesthesia, tumor size, and tumor number.

Major finding:  The adjusted odds ratios for the independent predictors of fever in these patients were 0.96 for younger age, 0.49 for low serum albumin level, 2.06 for general anesthesia, 1.52 for tumor size, and 1.71 for tumor number. HCC patients who developed fevers after radiofrequency ablation also had significantly longer hospital stays than those without fevers (9.06 days vs 5.50 days).

Study details: The data come from a retrospective study of 272 adults with new or recurrent hepatocellular carcinoma who underwent ultrasonography-guided radiofrequency ablation (RFA) between April 2014 and February 2019.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Chen P-Y et al. Cancers (Basel). 2021 Oct 22. doi: 10.3390/cancers13215303.

Key clinical point: Fever following radiofrequency ablation in hepatocellular carcinoma patients was independently associated with younger age, low serum albumin level, general anesthesia, tumor size, and tumor number.

Major finding:  The adjusted odds ratios for the independent predictors of fever in these patients were 0.96 for younger age, 0.49 for low serum albumin level, 2.06 for general anesthesia, 1.52 for tumor size, and 1.71 for tumor number. HCC patients who developed fevers after radiofrequency ablation also had significantly longer hospital stays than those without fevers (9.06 days vs 5.50 days).

Study details: The data come from a retrospective study of 272 adults with new or recurrent hepatocellular carcinoma who underwent ultrasonography-guided radiofrequency ablation (RFA) between April 2014 and February 2019.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Chen P-Y et al. Cancers (Basel). 2021 Oct 22. doi: 10.3390/cancers13215303.